Targeting NINJ1 protein could make donor livers more resilient
Peer-Reviewed Publication
Updates every hour. Last Updated: 30-Oct-2026 16:16 ET (30-Oct-2026 20:16 GMT/UTC)
She’s a Grammy Award-winning international superstar, and now, Taylor Swift is also a genus of plant-feeding insects from Australia that were previously unknown to science.
Researchers at VCU Massey Comprehensive Cancer Center were recently awarded a $2.5 million R01 grant from the National Cancer Institute. The five-year grant will allow Massey to evaluate the efficacy of TROP2 targeted antibody-drug conjugates (ADCs) to further enhance therapeutic benefits in both breast and pancreatic cancer care.
Massey researchers, led by principal investigator Chuck Harrell, Ph.D., member of the Cancer Biology research program at Massey and professor in the Department of Pathology at the VCU School of Medicine, will look to define what enables responses and resistance to ADCs in order to identify predictive biomarkers and establish therapeutic strategies to optimize TROP2-targeted ADC efficacy in both triple-negative breast cancer (TNBC) and pancreatic ductal adenocarcinoma (PDAC).
A new method developed by Virginie Ruetten, a postdoctoral scientist in the lab of Janelia Senior Group Leader Misha Ahrens, enables scientists to image the activity of nearly every cell in a living larval zebrafish, providing a never-before-seen look at cellular signaling and body-wide circuits across a behaving vertebrate.
The work is based on reading the complete DNA of 959 tumours from men in seven countries — the largest set of prostate cancer genomes examined in this way. Eight faulty cellular processes together account for the DNA damage in 85% of prostate cancers. Most tumours are driven by several of the eight at once, and what differs between patients is which ones and in what balance. “The balance of these faulty processes is what determines how likely the cancer is to spread,” says Geoff Macintyre, head of the Computational Oncology Group at the CNIO, who co-led the study. The processes are almost all internal to the cell: hormone signalling, failures in DNA copying and repair, and ageing. The marks that tobacco and sunlight leave on other cancers are practically absent.These results offer clues that could help stratify patients and personalise treatment — but not yet.
Weight loss injections are an increasingly popular way for people to manage their weight. However, the injections’ impact on reproductive health – from fertility onwards – is relatively unknown.
Now an international study led by the University of Plymouth has examined available research to understand what science tells us to date, and use that to form a set of evidence-based guidelines for families and health professionals seeking to understand if and when incretin-based medications – such as weight loss injections – could be used safely before and after pregnancy.